• iRhom2 Regulation in Olfactory Sensory Neurons: Mechanistic

  2026-07-26

  This study uncovers the unique role of iRhom2 in olfactory sensory neurons, highlighting its involvement in odorant receptor regulation and activity-dependent adaptation. The findings illuminate a negative feedback mechanism linking odor stimulation to transcriptional changes, with implications for understanding olfactory signaling and gene regulation.

• Antipyrine in High-Throughput BBB Models: Protocols & Insigh

  2026-07-25

  Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) is redefining CNS permeability and pharmacokinetic workflows with unmatched purity and solubility. Explore how this benchmark research compound, sourced from APExBIO, streamlines experimental design, boosts reproducibility, and overcomes common pitfalls in blood-brain barrier (BBB) model optimization.

• GSK126 EZH2 Inhibitor: Precision Tools for Cancer Epigenetic

  2026-07-24

  GSK126 stands out as a highly selective EZH2 inhibitor enabling targeted epigenetic modulation in oncology research. Its potent activity against mutant PRC2 complexes and compatibility with diverse experimental models position it as a cornerstone for dissecting gene silencing and tumor progression. Discover how optimized workflows, troubleshooting, and new biological insights can drive your next breakthrough using GSK126.

• RG108 DNA Methyltransferase Inhibitor: Protocols and Pitfall

  2026-07-24

  RG108 from APExBIO enables precise, non-covalent inhibition of DNA methyltransferases for epigenetic gene regulation studies. This guide delivers actionable protocols, workflow enhancements, and troubleshooting strategies to empower cancer and stem cell researchers seeking robust demethylation with minimal off-target effects.

• Antiarrhythmic Drugs and KCa2 Channel Modulation in AF Resea

  2026-07-23

  This study systematically investigated whether established antiarrhythmic agents for atrial fibrillation, including Dronedarone (Multaq), modulate small conductance calcium-activated potassium (KCa2) channels—a promising atrial-selective target. The findings reveal that most clinically used drugs, including Dronedarone, do not significantly inhibit KCa2 channels at therapeutic concentrations, underscoring a gap in current AF pharmacotherapy and pointing to the need for novel atrial-selective approaches.

• Angiotensin II (SKU A1042): Protocols for Vascular Research

  2026-07-23

  Angiotensin II (SKU A1042) is a peptide tool for modeling hypertension, vascular remodeling, and smooth muscle cell hypertrophy in preclinical workflows. It should be used where precise, GPCR-mediated vasopressor effects are essential, but is not intended for diagnostic or therapeutic applications.

• GST-Mediated Lambda-Cyhalothrin Resistance in M. usitatus

  2026-07-22

  This study reveals that glutathione S-transferase (GST) activity is central to Megalurothrips usitatus resistance against the insecticide lambda-cyhalothrin by strengthening antioxidant defenses. Inhibiting GST with diethyl maleate significantly increases insecticide susceptibility, offering mechanistic insights for resistance management and oxidative stress research.

• Telmisartan in Cardiovascular Research: Advanced Pathway Ins

  2026-07-22

  Explore the unique role of Telmisartan as a potent angiotensin II receptor antagonist in cardiovascular disease research. This article delivers advanced mechanistic insights and practical protocol guidance, positioning Telmisartan as a cornerstone for studies on cardiac hypertrophy and signaling modulation.

• Z-LEHD-FMK: Applied Workflows with an Irreversible Caspase-9

  2026-07-21

  Z-LEHD-FMK enables precise dissection of mitochondria-mediated apoptosis, offering selective and irreversible caspase-9 inhibition for advanced apoptosis assays across cancer and neuroprotection research. This article details robust protocols, troubleshooting, and practical guidance to maximize reproducibility and specificity—bridging evidence-backed workflows with the latest findings in cell death pathways.

• Pioglitazone as a PPARγ Agonist: Protocols and Applied Insig

  2026-07-21

  Pioglitazone, a selective PPARγ agonist from APExBIO, is redefining metabolic and inflammatory research workflows by enabling precise control of macrophage polarization and immune modulation. This article distills advanced experimental approaches, protocol enhancements, and troubleshooting strategies that harness pioglitazone’s unique mechanistic profile.

• Isochlorogenic Acid A Targets RIP3 to Inhibit Cardiac Hypert

  2026-07-20

  This study reveals that isochlorogenic acid A (ICAA) directly inhibits RIP3, suppressing the RIP3/CaMKII pathway to alleviate angiotensin II-induced cardiac hypertrophy. The findings identify a previously unrecognized therapeutic mechanism, offering new directions for cardiovascular disease research and experimental cardiac models.

• FGF4-FGFR1 Signaling Preserves Podocytes in Diabetic Kidney

  2026-07-20

  This study identifies podocyte-secreted FGF4 as a critical endogenous factor that preserves glomerular function and mitigates diabetic kidney disease (DKD) in male mice. By uncovering the protective FGF4-FGFR1-AMPK-FOXO1 pathway, the work highlights new mechanistic targets for renal injury intervention and broadens the landscape for future DKD therapies.

• Medroxyprogesterone Acetate: Mechanisms & Benchmarks in Rese

  2026-07-19

  Medroxyprogesterone acetate (MPA) is a synthetic steroidal progestin widely used in biomedical research for studying hormone signaling, renal cell function, and reproductive processes. It acts through both progesterone and glucocorticoid receptors, with distinct molecular and physiological effects validated in cellular and animal models. This article provides atomic, evidence-backed insights and protocol guidance for effective MPA application.

• Methotrexate as a Folate Antagonist: Applied Research Workfl

  2026-07-18

  Methotrexate’s unique profile as a folate antagonist enables researchers to precisely dissect immunosuppressive and apoptotic mechanisms in vitro and in vivo. This guide details advanced assay designs, protocol enhancements, and troubleshooting strategies for extracting maximal value from Methotrexate in translational studies.

• Wnt/β-catenin-Driven Soluble PD-L1 Suppresses CD8+ T Cells i

  2026-07-17

  This study identifies the Wnt/β-catenin pathway as a critical driver of soluble PD-L1 (sPD-L1) production in glioma, leading to impaired CD8+ T cell activity and poorer prognosis. The findings highlight sPD-L1 as a promising non-invasive biomarker and reveal potential therapeutic synergy between Wnt and PD-L1 pathway inhibition.

450 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page